Vestal Point Capital’s Nurix Therapeutics NRIX Stock Holding History

Vestal Point Capital’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$195M	Buy	8,050,000 +1,550,000	+24%	+$26.4M	4.56%	6
2026 Q1	$101M	Buy	6,500,000 +1,810,000	+39%	+$30M	2.82%	9
2025 Q4	$89M	Buy	4,690,000 +1,215,000	+35%	+$17.5M	3.02%	7
2025 Q3	$32.1M	Buy	3,475,000 +1,475,000	+74%	+$15.3M	1.45%	27
2025 Q2	$22.8M	Buy	2,000,000 +874,448	+78%	+$9.45M	1.2%	33
2025 Q1	$13.4M	Buy	1,125,552 +640,552	+132%	+$10.7M	0.95%	34
2024 Q4	$9.14M	Buy	485,000 +60,000	+14%	+$1.38M	0.54%	45
2024 Q3	$9.55M	Sell	425,000 -75,000	-15%	-$1.7M	0.72%	35
2024 Q2	$10.4M	Buy	+500,000	New	+$7.79M	0.78%	34

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vestal Point Capital's NRIX Position: Q2 2026 in Review

Vestal Point Capital increased its Nurix Therapeutics (NRIX) stake by 24% in Q2 2026, buying an estimated $26.4M and bringing the position to 8,050,000 shares worth $195M. The position accounts for 4.56% of the portfolio, ranked #6.

Vestal Point Capital first reported a position in NRIX in Q2 2024 and has held it in 9 quarters since. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

Vestal Point Capital held 8,050,000 shares of Nurix Therapeutics worth $195M as of Q2 2026.
Vestal Point Capital bought 1,550,000 Nurix Therapeutics shares in Q2 2026, an estimated $26.4M.
Nurix Therapeutics made up 4.56% of Vestal Point Capital's portfolio in Q2 2026, its #6 holding.
Vestal Point Capital first reported a position in Nurix Therapeutics in Q2 2024 and has held it in 9 quarters since.
212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.